Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Rule 425 Communication · 425

ENDRA Life Sciences Inc.

NDRANASDAQEQUITYCurrent

Rule 425 Communication

Filed Jun 26, 2026Accepted Jun 26, 2026, 6:16 AM EDTCIK 1681682Accession 0001213900-26-072270
Share

Company context

Inc. ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS® is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. Our press releases and financial and other material information are routinely posted to and accessible on the Investors section of our website, www.endrainc.com.

Current securities

Historical securities (1)

Recent company filings

  1. 425 filingSep 25, 2026
  2. 425 filingSep 14, 2026
  3. 425 filingAug 17, 2026
  4. Results of Operations and Financial ConditionAug 17, 2026
  5. 10-Q filingAug 14, 2026

As-filed source

Primary evidence